Principal Investigator
Overview
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Tanya Vasyukhnik, Research Manager
Phone
Email Address
Purpose of Study
Clostridium difficile infection (CDI) affects 37,000 patients in Canada annually. Even with successful treatment, approximately 25 per cent of patients develop recurrent CDI within eight weeks. The purpose of this study is to investigate whether the extension of initial treatment from 14 to 28 days with a tapering dose of vancomycin will help prevent recurrent CDI in the future.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Tanya Vasyukhnik, Research Manager
Phone
Email Address
Purpose of Study
Clostridium difficile infection (CDI) affects 37,000 patients in Canada annually. Even with successful treatment, approximately 25 per cent of patients develop recurrent CDI within eight weeks. The purpose of this study is to investigate whether the extension of initial treatment from 14 to 28 days with a tapering dose of vancomycin will help prevent recurrent CDI in the future.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
